Journal of Hypertension最新文献

{"title":"Automated office blood pressure measurement: a Hypertension Australia and National Hypertension Taskforce of Australia position statement.","authors":"James E Sharman, Aletta E Schutte, Mark R Nelson, Ania L Samarawickrama, Nigel Stocks, Charlotte M Hespe, Tim Usherwood, Michael Stowasser, Anthony Rodgers, Natalie C Ward, Elizabeth Halcomb, Sharon James, Garry Jennings, Markus P Schlaich","doi":"10.1097/HJH.0000000000004079","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004079","url":null,"abstract":"<p><p>Hypertension is the most common problem managed in Australian general practice, yet most adults with hypertension do not have their blood pressure (BP) treated to target. Hypertension diagnosis and management rely upon accurate BP measurements performed using a standardised protocol. However, health system barriers prevent doctors from following measurement protocols, leading to inaccurate BP assessments. A practical BP measurement protocol that can be widely implemented is urgently warranted. Automated office BP (AOBP) is the recommended measurement standard for the diagnosis and management of hypertension. AOBP involves using a validated automated upper-arm cuff BP device programmed to record multiple BP readings at set intervals starting after a rest period. It is done by a trained operator using a standardised protocol in a quiet setting with the correct patient setup, no distractions, and in the absence of a doctor. The device automatically calculates the average of the AOBP recordings and this is comparable to the 24-h ambulatory BP daytime mean. The hypertension threshold based on AOBP is 135/85 mmHg. AOBP can also be applied in other community settings (e.g. pharmacies), provided all the above criteria are met along with communication of results to the person's usual general practitioner. In Australia, nation-wide systematic implementation of evidence based AOBP measurement is strongly recommended. This standardised approach will support healthcare professionals, especially general practitioners, in obtaining high-quality BP values with increasing confidence in clinical decision-making. Policy and practice changes, to address barriers and provide enabling mechanisms for sustained implementation of AOBP, are required.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Betaine protects cerebral microvascular endothelium and ameliorates hypertension-induced cognitive dysfunction via upregulation of the endothelial nitric oxide synthase/nitric monoxide signaling pathway.","authors":"Jiale Sun, Wenjuan Zhang, Xueying Wang, Xiaomin Zhao, Shan Gao","doi":"10.1097/HJH.0000000000004085","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004085","url":null,"abstract":"<p><strong>Objectives: </strong>Hypertension-induced endothelial damage in cerebral microvessels is a key factor contributing to vascular cognitive impairment (VCI). Endothelial function stabilization considerably depends on the endothelial nitric oxide synthase (eNOS)/nitrogen monoxide (NO) pathway. Furthermore, the eNOS/NO signaling pathway plays a role in stabilizing the vascular endothelium. Although betaine (bet) has been shown to improve cognitive dysfunction, its underlying mechanisms remain unclear. Therefore, this study aimed to determine whether betaine protects cognitive function by regulating eNOS/NO activity.</p><p><strong>Methods: </strong>Male 7-month-old spontaneously hypertensive rats (SHR) were randomly assigned to four groups: SHR, Bet, Bet and N(G)-Nitroarginine methyl ester hydrochloride (L-NAME), and L-NAME groups. Male 7-month-old Wistar Kyoto rats (WKY) served as controls. All animals received treatment or saline for 4 weeks. In-vitro experiments were conducted using rat brain microvascular endothelial cells (RBMECs) treated with either homocysteine (Hcy) or betaine. Behavioral experiments, western blotting, pathological tissue staining, Doppler ultrasound technique, and ELISA were employed to assess the impact of hypertension on cognitive and endothelial functions.</p><p><strong>Results: </strong>Hypertension led to cognitive decline in SHR by causing endothelial dysfunction, blood-brain barrier disruption, inflammation, oxidative stress, and apoptosis. Bet administration significantly improved these pathological indicators of cognitive impairment; however, the eNOS inhibitor L-NAME reversed its effects.</p><p><strong>Conclusion: </strong>Our findings suggest that betaine protects vascular endothelium and improves VCI by modulating the eNOS/NO signaling pathway.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined percutaneous renal artery denervation and angioplasty: still too early to consider them complementary?","authors":"Fortunato Iacovelli, Luigi Salemme, Rocco Tritto, Sebastiano Cicco, Filippo Masi, Loreto Gesualdo, Marco Matteo Ciccone","doi":"10.1097/HJH.0000000000004078","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004078","url":null,"abstract":"<p><p>In case of renovascular hypertension, percutaneous renal artery transluminal angioplasty alone is still far from demonstrating predictable clinical results. Assuming a potential synergistic effect, we reported the first case of combined percutaneous renal denervation and angioplasty as intention-to-treat strategy in a very high cardiovascular risk patient.</p><p><strong>Graphical abstract: </strong>http://links.lww.com/HJH/C752.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of high-density lipoprotein cholesterol, particles and subspecies with the risk of hypertension: findings from the PREVEND prospective study.","authors":"Setor K Kunutsor, Margery A Connelly, Ashish Shah, Stephan J L Bakker, Robin P F Dullaart","doi":"10.1097/HJH.0000000000004014","DOIUrl":"10.1097/HJH.0000000000004014","url":null,"abstract":"<p><strong>Objective: </strong>The prospective associations of high-density lipoprotein cholesterol (HDL-C), HDL particle (HDL-P) and subspecies concentrations with the risk of hypertension are uncertain. We aimed to evaluate the associations of HDL parameters with incident hypertension risk and their interplay with alcohol consumption in the PREVEND study.</p><p><strong>Methods: </strong>HDL parameters as measured by nuclear magnetic resonance spectroscopy and self-reported alcohol consumption were assessed in 3263 participants (mean age, 49 years; 45.8% males) without a history of hypertension at baseline. Multivariable-adjusted hazard ratios (HRs) with 95% CIs for hypertension per 1 standard deviation increment in HDL parameters were calculated.</p><p><strong>Results: </strong>During a median follow-up of 7.2 years, 825 participants developed hypertension. In analysis adjusted for several potential confounders, including alcohol consumption, there were inverse associations of HDL-C, HDL-P, medium HDL, HDL size, H3P and H4P with hypertension risk: HRs [95% confidence interval (CI) of 0.88 (0.81-0.97), 0.92 (0.86-0.99), 0.86 (0.80-0.93), 0.89 (0.82-0.98), 0.92 (0.85-0.98), and 0.87 (0.81-0.94), respectively]. Sex or alcohol consumption did not modify the associations of HDL parameters with hypertension risk. Compared with abstainers, the multivariable adjusted HRs (95% CI) of hypertension for occasional to light, moderate and heavy alcohol consumers were 0.84 (0.70-1.00), 0.83 (0.68-1.02), and 0.97 (0.69-1.37), respectively; the associations persisted on further adjustment for HDL parameters.</p><p><strong>Conclusions: </strong>There are inverse associations of HDL-C, HDL-P, medium HDL, HDL size, H3P and H4P with hypertension risk, which are not confounded or modified by alcohol consumption. Light and moderate alcohol consumption is modestly and inversely associated with hypertension risk, independently of HDL parameters.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1066-1074"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage.","authors":"Martina Hüttl, Matúš Miklovič, Olga Gawryś, Matěj Molnár, Petra Škaroupková, Zdeňka Vaňourková, Soňa Kikerlová, Hana Malínská, Petr Kala, Zuzana Honetschlägerová, Janusz Sadowski, Lenka Hošková, Peter Sandner, Vojtěch Melenovský, Miloš Táborský, Michal Šnorek, Luděk Červenka","doi":"10.1097/HJH.0000000000004009","DOIUrl":"10.1097/HJH.0000000000004009","url":null,"abstract":"<p><strong>Objective: </strong>Despite availability of an array of antihypertensive drugs, malignant hypertension remains a life-threatening condition, and new therapeutic strategies for the treatment of malignant hypertension and malignant hypertension-associated organ damage are needed. The aim of the present study was to assess the effects of nitric oxide (NO)-independent soluble guanylyl cyclase (sGC) stimulator on the course of malignant hypertension. The second aim was to investigate if the treatment with sodium-glucose cotransporter type 2 (SGLT2) inhibitor would augment the expected beneficial actions of the sGC stimulation on the course of malignant hypertension.</p><p><strong>Methods: </strong>As a model of malignant hypertension, Ren-2 transgenic rats (TGR) treated with nonspecific NO synthase inhibitor (Nω-nitro- l -arginine methyl ester, l -NAME) was used. Blood pressure (BP) was monitored by radiotelemetry, and the treatment was started 3 days before administration of l -NAME.</p><p><strong>Results: </strong>The treatment with sGC stimulator BAY 41-8543, alone or combined with SGLT2 inhibitor empagliflozin, abolished malignant hypertension-related mortality in TGR receiving l -NAME. These two treatment regimens also prevented BP increases after l -NAME administration in TGR, and even decreased BP below values observed in control TGR, and prevented cardiac dysfunction and malignant hypertension-related morbidity. The treatment with the SGLT2 inhibitor empagliflozin did not further augment the beneficial actions of sGC stimulator on the course of malignant hypertension-related mortality.</p><p><strong>Conclusion: </strong>The treatment with NO-independent sGC stimulator displayed marked protective actions on the course of malignant hypertension-related mortality and malignant hypertension-related cardiac damage. This suggests that application of sGC stimulator could be a promising therapeutic means for the treatment of malignant hypertension.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1030-1041"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on: \"Long-term cardiovascular repercussions in women with previous pregnancies complicated by severe hypertensive disease\".","authors":"Elizabeth C Cottrell","doi":"10.1097/HJH.0000000000004028","DOIUrl":"https://doi.org/10.1097/HJH.0000000000004028","url":null,"abstract":"","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":"43 6","pages":"949-950"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for chronic hypertension 5 years after a pregnancy complicated by preeclampsia: a systematic review and meta-analysis.","authors":"Lotte W Voskamp, Melek Rousian, Joni J Koerts, Régine P M Steegers-Theunissen, A H Jan Danser, Koen Verdonk","doi":"10.1097/HJH.0000000000003995","DOIUrl":"10.1097/HJH.0000000000003995","url":null,"abstract":"<p><p>Approximately 30% of women with a history of preeclampsia develop chronic hypertension within 10 years of pregnancy. This systematic review summarizes risk factors before, during, and immediately after pregnancy for the development of chronic hypertension 5 years after preeclampsia. Databases were searched with terms 'preeclampsia' and 'postpartum hypertension' or 'cardiovascular disease' up to 30th October 2023. Observational studies reporting chronic hypertension more than 5 years after preeclampsia were included. Quality was assessed using the Newcastle-Ottawa scale. Wherever possible, a meta-analysis was conducted. Twenty-one cohort and five case-control studies, with a median quality score of 8/10, were included, involving 197 793 patients and reporting 32 risk factors. Preeclampsia in a subsequent pregnancy is associated with chronic hypertension [risk ratio (RR) 2.26, 95% confidence interval (CI) 1.59-3.22, n  = 45 626]. Other significant risk factors include early-onset of preeclampsia (<34 weeks gestation), maternal BMI, blood pressure, diabetes, and family history of hypertension.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"939-948"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of pulmonary to systemic vascular resistance ratio in systemic lupus erythematosus patients with pulmonary arterial hypertension.","authors":"Xiaoxiao Guo, Junyan Qian, Jinzhi Lai, Hui Wang, Zhuang Tian, Qian Wang, Jiuliang Zhao, Xiaofeng Zeng, Mengtao Li, Yongtai Liu","doi":"10.1097/HJH.0000000000004010","DOIUrl":"10.1097/HJH.0000000000004010","url":null,"abstract":"<p><strong>Objective: </strong>Pulmonary arterial hypertension (PAH) is a serious complication of systemic lupus erythematosus (SLE) with high mortality. The ratio of pulmonary to systemic vascular resistance (SVR) (Rp : Rs) may increase with disease progression. However, the prognostic value of Rp : Rs in predicting the outcomes of patients with SLE-PAH remains to be elucidated.</p><p><strong>Methods: </strong>Between 1 February 2012, and 30 June 2022, consecutive patients with a diagnosis of SLE-PAH and minimum one follow-up were enrolled prospectively. The end points were all-cause mortality and lung transplantation. The predictive values of baseline clinical characteristics and hemodynamic parameters, including Rp : Rs, were analyzed using Cox proportional hazard analyses. C-statistics were used to compare the predictive ability between the models.</p><p><strong>Results: </strong>A total of 285 patients were included and followed up for a median duration of 3.41 (interquartile range 1.81-5.72), during which 58 (20.4%) patients reached the endpoint. Multivariable Cox regression analysis revealed that in addition to the 6-minute walk distance (6MWD), the Rp : Rs was an independent predictor of the endpoint [hazard ratio 24.72; 95% confidence interval (CI) 5.59-109.29, P  < 0.001] in predicting the endpoint. The concordance index for a model incorporating the Rp : Rs and the 6MWD yielded a value of 0.75 (95% CI 0.68-0.82), which showed better predictive accuracy than the simplified risk stratification strategy. Introducing the Rp : Rs ratio to the 2022 ESC/ERS four-stratum model significantly improved its predictive performance for these patients.</p><p><strong>Conclusion: </strong>The Rp : Rs serves as an independent predictor of adverse prognosis in patients with SLE-PAH and could provide additional value over current risk-assessment tools.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1042-1048"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effects of SARS-CoV-2 infection on blood vessels and blood pressure - LOCHINVAR.","authors":"Stefanie Lip, Tran Q B Tran, Rebecca Hanna, Sarah Nichol, Tomasz J Guzik, Christian Delles, John McClure, Linsay McCallum, Rhian M Touyz, Colin Berry, Sandosh Padmanabhan","doi":"10.1097/HJH.0000000000004013","DOIUrl":"10.1097/HJH.0000000000004013","url":null,"abstract":"<p><strong>Objective: </strong>The COVID-19 pandemic has been linked to endothelial dysfunction and renin-angiotensin-aldosterone system (RAAS) dysregulation, potentially worsening hypertension. Longitudinal studies are needed to establish COVID-19's lasting effects on blood pressure (BP) and endothelial function. Our objective was to determine whether COVID-19 increases future hypertension risk by comparing BP and endothelial function in nonhypertensive COVID-19 survivors with nonhypertensive controls.</p><p><strong>Methods: </strong>This single-centre prospective longitudinal study included participants without hypertension history, with cases being hospital-admitted COVID-19 survivors and controls having negative SARS-CoV-2 antibody tests. Ambulatory blood pressure monitoring, flow-mediated dilatation (FMD), 6-min walk test (6MWT), and quality of life (QoL) assessments were conducted at baseline and 12 months. RAAS phenotyping was performed at baseline. Data analysis used paired t-tests and multivariable regression on full and per-protocol datasets.</p><p><strong>Results: </strong>The full ( n  = 97) and per-protocol ( n  = 66) datasets included 37 and 15 cases respectively. Median ages (IQR: interquartile range) were 49.0 (43.0-53.5) and 50.0 (42-54.0) years. Baseline RAAS parameters were similar. Multivariable adjusted analyses in the per-protocol group showed SARS-CoV-2 positive participants had a 12-month increase in mean systolic BP (4.57 mmHg, [95% CI -0.04 to 9.18], P  = 0.052), diastolic BP (4.46 mmHg [1.01 to 7.90], P  = 0.012), decrease in FMD (-3.15% [-6.33 to 0.04], P  = 0.053) and improvement in 6MWT (145.6 m [49.1 to 242.1], P  = 0.004) compared to controls. QoL assessments indicated continued challenges for recovered COVID-19 individuals at 12 months.</p><p><strong>Conclusions: </strong>Persistent vascular dysfunction and BP increase post-COVID-19 underscore the need for further studies on the long-term risk of hypertension and cardiovascular disease.</p><p><strong>Clinical trial registration: </strong>https://clinicaltrials.gov/study/NCT05087290.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1057-1065"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of incidence of hypertension in France and associated factors: results from the CONSTANCES cohort.","authors":"Lynda Cheddani, Hélène Lelong, Marcel Goldberg, Marie Zins, Jacques Blacher, Sofiane Kab","doi":"10.1097/HJH.0000000000003989","DOIUrl":"10.1097/HJH.0000000000003989","url":null,"abstract":"<p><strong>Introduction: </strong>Estimating hypertension incidence and improving screening in general population could enhance blood pressure control and decrease cardiometabolic risks. Identifying those likely to develop hypertension is essential. Our study focused on predicting onset hypertension and its incidence based on initial characteristics.</p><p><strong>Methods: </strong>We utilized data from the French prospective CONSTANCES cohort, including volunteers assessed twice over 5 years up to 31 December 2019, who were initially free from hypertension. Hypertension was defined as having a SBP at least 140 mmHg or DBP at least 90 mmHg during the second checkup or if antihypertensive medication was prescribed. We calculated annual incidence rates among subgroups and used machine learning models to identify predictors of hypertension. The impact of changes in BMI was analyzed using logistic regression.</p><p><strong>Results: </strong>Of the 11 112 participants (average age 47.5 ± 12 years), 1929 (17.4%) developed hypertension within an average of 5.2 years, with 383 on medication. The incidence rate was 3.4 new cases per 100 person-years, rising with age and consistently higher in men (4.3 vs. 2.8). A blood pressure (BP) threshold of 130 mmHg predicted 70% of new cases. One-point BMI reduction significantly reduced hypertension risk by 16%, regardless of initial BMI and SBP levels.</p><p><strong>Conclusion: </strong>The study reports a notable hypertension incidence of 3.4 new cases per 100 person-years, particularly among those with SBP over 130 mmHg, highlighting the need for regular screening. Early diagnosis and control can mitigate hypertension's adverse effects, emphasizing the crucial role of preventive measures like BMI reduction.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"976-985"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143501844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}